In an embarrassing rebuke, the Food and Drug Administration has scolded Amgen (AMGN) over an advertisement for one of its medicines that made misleading claims and, as a result, might confuse ...
On June 16, 2021, the District Court for the District of Delaware issued a claim construction order construing a key term in the ongoing patent dispute between Amgen and Hospira over Hospira’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback